Replies to post #1015 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

>IDIX could surprise us with that " creative approach " they've been hiding from us. ;) <

The "creative approach" is quadruple therapy for partial responders to first-line SoC. I think this is clear from the MS webcast.